乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义

目的　检测tRNA 及其来源片段（tRNA-derived fragments）- tRF-32-Q99P9P9NH57SJ（tRF-32）在乳腺癌患者血清中的表达及意义。方法　选取2017 年11 月~ 2019 年2 月在江苏省肿瘤医院乳腺外科确诊的51 例乳腺癌患者及同期25 例健康对照者的血清，记录患者临床资料。运用RT-PCR 检测血清tRF-32 的表达水平，分析其表达水平与临床病理资料的关系。结果　51 例乳腺癌患者血清中tRF-32 的表达量（13.84 ± 2.62）与25 例健康对照组血清中的tRF-32 表达量（39.47 ± 7.21）比较，差异有统计学意义（t = 4.091, P < 0.000 1）。临床TNM 分期I-II 期的tRF-32 表达量（16.97± 3.315）明显高于 III-IV 期tRF-32 表达量（7.07 ± 2.83），差异有统计学意义（t = 2.241, P = 0.029）。无淋巴结转移患者血清中的tRF-32 表达量 (18.75 ± 3.91) 明显高于有淋巴结转移患者血清中tRF-32 表达量（7.80 ± 2.51)，差异有统计学意义（t = 2.47, P = 0.017）。乳腺癌患者tRF-32 表达量与年龄无关（χ2=0.621，P >0.05），与TNM 临床分期（χ2=8.463,P = 0.004）以及淋巴结是否转移相关（χ2 =5.856, P = 0.016）。受试者工作曲线（receiver operating characteristic curve,ROC）显示血清tRF-32 诊断乳腺癌的曲线下面积（area under curve, AUC）是0.776（95% CI: 0.673 ~ 0.880），敏感度和特异度分别为84.0 % 和68.8%。结论　tRF-32 在乳腺癌患者血清中低表达，tRF-32 的表达水平与乳腺癌的临床分期和淋巴结转移有关。

Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serumof Patients with Breast Cancer

Objective　To investigate the expression and significance of tRF-32 in breast cancer serum. Methods　The serumsamples were collected form 51 patients with breast cancer in Jiangsu Cancer Hospital from November 2017 and February 2019,at the same time serum form 25 healthy controls were collected. The clinical data of patients were recorded. The expression levelof tRF-32 was detected by RT-PCR, and analyzed its relationship with clinicopathologic factor of patients with breast cancer.Results　The serum level of tRF-32 in 51 patients with breast cancer (13.84 ± 2.62) was different form that in 25 healthycontrol group (39.47 ± 7.21) and they had statistical difference (t = 4.091, P < 0.000 1). Serum tRF-32 in patients with breastcancer was significantly difference between TNM stage I-II and stage III-IV (t = 2.241, P = 0.029). Meanwhile, the expression oftRF-32 in patients without lymph node metastasis was higher than those with lymph node metastasis (t = 2.47, P = 0.017). Thelevel of serum tRF-32 was no correlated with ages (χ2=0.621，P >0.05). While there were significant association with TNM stage (χ2=8.463, P = 0.004) and lymph node metastasis (χ2 =5.856, P = 0.016). Finally, the ROC-AUC for tRF-32 was 0.776 (95% CI: 0.673~0.880) for differentiating breast cancer patients from healthy controls, with a sensitivity of 84.0% and specificity of 68.8%.Conclusion tRF-32 was lower expression in patient’s serum with breast cancer. The expression level of tRF-32 was related tothe clinical stage and lymph node metastasis of breast cancer.